Ramucirumab (Cyramza) — CPB 0883 | AETNA Coverage Update

Aetna modified CPB 0883 for ramucirumab (Cyramza), effective December 20, 2025. Here's what changes for billing teams.

Aetna, a CVS Health company, updated its coverage policy for ramucirumab (Cyramza) under CPB 0883 Aetna system, effective December 20, 2025. This update affects oncology billing across six cancer types, with J9308 (ramucirumab, 5 mg) as the primary covered HCPCS code. Billing teams who manage claims for gastric, lung, colorectal, liver, mesothelioma, or thymic carcinoma patients need to review the updated criteria before submitting new authorizations.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Ramucirumab (Cyramza) — CPB 0883
Policy Code	CPB 0883
Change Type	Modified
Effective Date	December 20, 2025
Impact Level	High
Specialties Affected	Medical Oncology, Hematology/Oncology, GI Oncology, Thoracic Oncology
Key Action	Verify indication-specific criteria and combination regimen requirements before submitting prior authorization for J9308

---

Aetna Ramucirumab Coverage Criteria and Medical Necessity Requirements 2025

The Aetna ramucirumab coverage policy requires prior authorization for every claim. There are no exceptions for participating providers. Call (866) 752-7021 or fax (888) 267-3277 to initiate precertification. You can also use the Statement of Medical Necessity form through Aetna's Specialty Pharmacy Precertification portal.

Aetna's medical necessity standard for J9308 is narrow and indication-specific. The drug must be used in an approved combination regimen or as a specified single agent. The wrong regimen pairing — even for a covered cancer type — will trigger a claim denial.

Gastric, GEJ, EGJ, and Esophageal Adenocarcinoma

Aetna covers ramucirumab for unresectable, locally advanced, recurrent, or metastatic disease when the patient is not a surgical candidate. Coverage applies to subsequent therapy only — not first-line. Approved regimens include single-agent ramucirumab, ramucirumab plus paclitaxel (J9267), and ramucirumab plus irinotecan (J9206) with or without fluorouracil (J9190).

Non-Small Cell Lung Cancer (NSCLC)

For NSCLC, this coverage policy covers two distinct paths. The first is ramucirumab plus docetaxel as subsequent therapy. The second is ramucirumab plus erlotinib — but only for EGFR exon 19 deletion or exon 21 (L858R) substitution mutation-positive disease.

That EGFR mutation requirement matters. You need CPT 81235 (EGFR gene analysis) results in the record before Aetna will authorize the erlotinib combination. Missing molecular documentation is one of the most common reasons this specific path gets denied. Pull the lab results before you submit.

Colorectal Cancer

Aetna covers ramucirumab for advanced or metastatic colorectal cancer — and this indication now explicitly includes anal adenocarcinoma (ICD-10 C21.0–C21.8) and appendiceal adenocarcinoma. Approved regimens are FOLFIRI (irinotecan J9206, folinic acid J0640, and 5-fluorouracil J9190) or irinotecan alone. This is a meaningful expansion worth noting if your practice treats anal or appendiceal primaries.

Hepatocellular Carcinoma (HCC)

Single-agent ramucirumab is covered for subsequent treatment of progressive HCC — but only when alpha-fetoprotein (AFP) is 400 ng/mL or greater. You must document the AFP lab value. Bill CPT 82105 (AFP, serum) or CPT 82107 (AFP-L3 fraction isoform and total AFP) and make sure the result ties directly to the authorization request. An AFP below the threshold means no coverage, full stop.

Mesothelioma

Aetna covers ramucirumab for subsequent treatment of pleural mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma. The covered regimen is ramucirumab plus gemcitabine (J9184, J9198, or J9201). Single-agent use is not covered for this indication.

Thymic Carcinoma

This is the most complex indication in CPB 0883. Aetna covers three separate clinical scenarios, all using ramucirumab plus carboplatin (J9045) plus paclitaxel (J9267):

#	Covered Indication Copy
1	Recurrent, advanced, or metastatic disease — with continuation as single-agent maintenance after the combination phase
2	R1 or R2 resection — as postoperative treatment
3	Surgically resectable disease where R0 resection is uncertain — as preoperative treatment

Document the resection status and surgical intent clearly in every prior authorization request. Aetna will be looking for it.

---

Aetna Ramucirumab Exclusions and Non-Covered Indications

Aetna labels all indications not listed in Section I of CPB 0883 as experimental, investigational, or unproven. That's a broad exclusion with real reimbursement consequences.

Two specific combinations are explicitly called out as not covered in the code descriptions. Cisplatin (J9060) is not covered in combination with ramucirumab. Dacarbazine (J9130) is not covered in combination with ramucirumab for pancreatic neuroendocrine tumors. If your physicians are using either of those regimens, don't bill J9308 expecting coverage — you'll get a denial.

Small-cell lung cancer is also explicitly excluded. The C34.x ICD-10 codes in CPB 0883 apply to non-small cell lung cancer only. Billing ramucirumab for a small-cell patient is not a gray area — it's non-covered.

---

Coverage Indications at a Glance

---

Aetna Ramucirumab Billing Guidelines and Action Items 2025

This policy took effect December 20, 2025. If your team has pending authorizations or active patients on ramucirumab, act now.

Copy Action Items

If your patient mix includes any off-label ramucirumab use or combinations not listed in Section I of CPB 0883, loop in your compliance officer before submitting. The "experimental or investigational" designation carries appeal restrictions and financial exposure that go beyond a routine denial.

---

CPT, HCPCS, and ICD-10 Codes for Ramucirumab Under CPB 0883

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J9308	HCPCS	Injection, ramucirumab, 5 mg

CPT Codes Related to CPB 0883

Combination Agent HCPCS Codes Referenced in CPB 0883

Key ICD-10-CM Diagnosis Codes

Note: CPB 0883 includes 193 ICD-10-CM codes in total. The ranges above represent the primary diagnosis categories. Verify the complete code list in the full policy document at the Aetna source before finalizing claim submissions.

---